Modality
mRNA
MOA
EZH2i
Target
PD-L1
Pathway
Epigenetic
Prostate Ca
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
~Mar 2019
→ ~Jun 2020
NDA/BLA
~Sep 2020
→ ~Dec 2021
Approved
Mar 2022
→ May 2029
ApprovedCurrent
NCT07803549
1,090 pts·Prostate Ca
2022-03→2029-05·Recruiting
1,090 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-05-193.1y awayPh3 Readout· Prostate Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Recruit…
Catalysts
Ph3 Readout
2029-05-19 · 3.1y away
Prostate Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07803549 | Approved | Prostate Ca | Recruiting | 1090 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |